Neil H Shear, Keith A Betts, Ahmed M Soliman, Avani Joshi, Yan Wang, Jing Zhao, Paolo Gisondi, Ranjeeta Sinvhal, April W Armstrong. J Am Acad Dermatol 2021
Times Cited: 5
Times Cited: 5
Times Cited
Times Co-cited
Similarity
Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.
April W Armstrong, Luis Puig, Avani Joshi, Martha Skup, David Williams, Junlong Li, Keith A Betts, Matthias Augustin. JAMA Dermatol 2020
April W Armstrong, Luis Puig, Avani Joshi, Martha Skup, David Williams, Junlong Li, Keith A Betts, Matthias Augustin. JAMA Dermatol 2020
80
Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
Richard B Warren, Melinda Gooderham, Russel Burge, Baojin Zhu, David Amato, Karen Huayu Liu, David Shrom, Jiaying Guo, Alan Brnabic, Andrew Blauvelt. J Am Acad Dermatol 2020
Richard B Warren, Melinda Gooderham, Russel Burge, Baojin Zhu, David Amato, Karen Huayu Liu, David Shrom, Jiaying Guo, Alan Brnabic, Andrew Blauvelt. J Am Acad Dermatol 2020
60
Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.
Najeeda Yasmeen, Laura M Sawyer, Kinga Malottki, Lars-Åke Levin, Eydna Didriksen Apol, Gregor B Jemec. J Dermatolog Treat 2022
Najeeda Yasmeen, Laura M Sawyer, Kinga Malottki, Lars-Åke Levin, Eydna Didriksen Apol, Gregor B Jemec. J Dermatolog Treat 2022
60
National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study.
Rosa Parisi, Ireny Y K Iskandar, Evangelos Kontopantelis, Matthias Augustin, Christopher E M Griffiths, Darren M Ashcroft. BMJ 2020
Rosa Parisi, Ireny Y K Iskandar, Evangelos Kontopantelis, Matthias Augustin, Christopher E M Griffiths, Darren M Ashcroft. BMJ 2020
60
Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.
S K Mahil, M C Ezejimofor, L S Exton, L Manounah, A D Burden, L C Coates, M de Brito, A McGuire, R Murphy, C M Owen,[...]. Br J Dermatol 2020
S K Mahil, M C Ezejimofor, L S Exton, L Manounah, A D Burden, L C Coates, M de Brito, A McGuire, R Murphy, C M Owen,[...]. Br J Dermatol 2020
60
Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response.
J E Signorovitch, K A Betts, Y S Yan, C LeReun, M Sundaram, E Q Wu, P Mulani. Br J Dermatol 2015
J E Signorovitch, K A Betts, Y S Yan, C LeReun, M Sundaram, E Q Wu, P Mulani. Br J Dermatol 2015
60
Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Yayoi Tada, Rei Watanabe, Hisashi Noma, Yasumasa Kanai, Takanobu Nomura, Kenji Kaneko. J Dermatol Sci 2020
Yayoi Tada, Rei Watanabe, Hisashi Noma, Yasumasa Kanai, Takanobu Nomura, Kenji Kaneko. J Dermatol Sci 2020
60
Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis.
Weiguang Xue, Paranjoy Saharia, Emma Gray, Shoghag Khoudigian-Sinani, Véronique Gaudet, Martin Barbeau, Kim Papp. J Cutan Med Surg 2020
Weiguang Xue, Paranjoy Saharia, Emma Gray, Shoghag Khoudigian-Sinani, Véronique Gaudet, Martin Barbeau, Kim Papp. J Cutan Med Surg 2020
60
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Sivem Afach, Liz Doney, Corinna Dressler, Camille Hua, Canelle Mazaud, Céline Phan, Carolyn Hughes, Dru Riddle,[...]. Cochrane Database Syst Rev 2020
Emilie Sbidian, Anna Chaimani, Sivem Afach, Liz Doney, Corinna Dressler, Camille Hua, Canelle Mazaud, Céline Phan, Carolyn Hughes, Dru Riddle,[...]. Cochrane Database Syst Rev 2020
60
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Liz Doney, Corinna Dressler, Camille Hua, Carolyn Hughes, Luigi Naldi, Sivem Afach, Laurence Le Cleach. Cochrane Database Syst Rev 2021
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Liz Doney, Corinna Dressler, Camille Hua, Carolyn Hughes, Luigi Naldi, Sivem Afach, Laurence Le Cleach. Cochrane Database Syst Rev 2021
40
Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
K Reich, A D Burden, J N Eaton, N S Hawkins. Br J Dermatol 2012
K Reich, A D Burden, J N Eaton, N S Hawkins. Br J Dermatol 2012
40
Indirect comparison of anti-interleukin 17 targeted biological treatments for moderate-to-severe psoriasis.
Rocío Díaz Acedo, Mercedes Galvan Banqueri, Esther Márquez Saavedra. J Clin Pharm Ther 2020
Rocío Díaz Acedo, Mercedes Galvan Banqueri, Esther Márquez Saavedra. J Clin Pharm Ther 2020
100
A Systematic Review With Network Meta-Analysis of the Available Biologic Therapies for Psoriatic Disease Domains.
Tiago Torres, Anabela Barcelos, Paulo Filipe, João Eurico Fonseca. Front Med (Lausanne) 2021
Tiago Torres, Anabela Barcelos, Paulo Filipe, João Eurico Fonseca. Front Med (Lausanne) 2021
40
Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method.
U Mrowietz, R B Warren, C L Leonardi, D Saure, H Petto, S Hartz, M Dossenbach, K Reich. J Eur Acad Dermatol Venereol 2021
U Mrowietz, R B Warren, C L Leonardi, D Saure, H Petto, S Hartz, M Dossenbach, K Reich. J Eur Acad Dermatol Venereol 2021
50
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Giao Do, Camille Hua, Canelle Mazaud, Catherine Droitcourt, Carolyn Hughes, John R Ingram, Luigi Naldi,[...]. Cochrane Database Syst Rev 2017
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Giao Do, Camille Hua, Canelle Mazaud, Catherine Droitcourt, Carolyn Hughes, John R Ingram, Luigi Naldi,[...]. Cochrane Database Syst Rev 2017
40
Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis.
Guomei Xu, Meng Xia, Chenjie Jiang, Ying Yu, Guomi Wang, Jiaojiao Yuan, Xingwu Duan. J Pharmacol Sci 2019
Guomei Xu, Meng Xia, Chenjie Jiang, Ying Yu, Guomi Wang, Jiaojiao Yuan, Xingwu Duan. J Pharmacol Sci 2019
40
The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.
Laura Sawyer, Iain Fotheringham, Emily Wright, Najeeda Yasmeen, Carl Gibbons, Anders Holmen Møller. J Dermatolog Treat 2018
Laura Sawyer, Iain Fotheringham, Emily Wright, Najeeda Yasmeen, Carl Gibbons, Anders Holmen Møller. J Dermatolog Treat 2018
40
Relative efficacy and safety of tofacitinib for treating psoriasis: A Bayesian network meta-analysis of randomized controlled trials.
Gwan Gyu Song, Young Ho Lee. Int J Clin Pharmacol Ther 2021
Gwan Gyu Song, Young Ho Lee. Int J Clin Pharmacol Ther 2021
50
Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.
F Gómez-García, D Epstein, B Isla-Tejera, A Lorente, A Vélez García-Nieto, J Ruano. Br J Dermatol 2017
F Gómez-García, D Epstein, B Isla-Tejera, A Lorente, A Vélez García-Nieto, J Ruano. Br J Dermatol 2017
40
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
Laura M Sawyer, Kinga Malottki, Celia Sabry-Grant, Najeeda Yasmeen, Emily Wright, Anne Sohrt, Emma Borg, Richard B Warren. PLoS One 2019
Laura M Sawyer, Kinga Malottki, Celia Sabry-Grant, Najeeda Yasmeen, Emily Wright, Anne Sohrt, Emma Borg, Richard B Warren. PLoS One 2019
40
A network meta-analysis for the comparison of efficacy and safety of interleukin (IL)-23 targeted drugs in the treatment of moderate to severe psoriasis.
Jianzhen Shi, Jianru Xu, Yanmei Chen. Dermatol Ther 2020
Jianzhen Shi, Jianru Xu, Yanmei Chen. Dermatol Ther 2020
40
Common pitfalls and mistakes in the set-up, analysis and interpretation of results in network meta-analysis: what clinicians should look for in a published article.
Anna Chaimani, Georgia Salanti, Stefan Leucht, John R Geddes, Andrea Cipriani. Evid Based Ment Health 2017
Anna Chaimani, Georgia Salanti, Stefan Leucht, John R Geddes, Andrea Cipriani. Evid Based Ment Health 2017
40
Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Fan Bai, Gang Gang Li, Qingmin Liu, Xinwu Niu, Ruilian Li, Huiqun Ma. J Immunol Res 2019
Fan Bai, Gang Gang Li, Qingmin Liu, Xinwu Niu, Ruilian Li, Huiqun Ma. J Immunol Res 2019
40
Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis.
Shanshan Xu, Xing Gao, Jixiang Deng, Jiajia Yang, Faming Pan. J Dtsch Dermatol Ges 2021
Shanshan Xu, Xing Gao, Jixiang Deng, Jiajia Yang, Faming Pan. J Dtsch Dermatol Ges 2021
66
Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses.
Richard B Warren, Kyoungah See, Russel Burge, Ying Zhang, Alan Brnabic, Gaia Gallo, Alyssa Garrelts, Alexander Egeberg. Dermatol Ther (Heidelb) 2020
Richard B Warren, Kyoungah See, Russel Burge, Ying Zhang, Alan Brnabic, Gaia Gallo, Alyssa Garrelts, Alexander Egeberg. Dermatol Ther (Heidelb) 2020
40
A Systematic Literature Review and Bucher Indirect Comparison: Tildrakizumab versus Guselkumab.
Kristian Garn Du Jardin, Pepi Hurtado Lopez, Mette Lange, Rachael McCool, Silvia Maeso Naval, Sandra Quickert. J Health Econ Outcomes Res 2020
Kristian Garn Du Jardin, Pepi Hurtado Lopez, Mette Lange, Rachael McCool, Silvia Maeso Naval, Sandra Quickert. J Health Econ Outcomes Res 2020
50
Comparison of Ustekinumab With Other Biological Agents for the Treatment of Moderate to Severe Plaque Psoriasis: A Bayesian Network Meta-analysis.
Vincent W Lin, Sarah Ringold, Emily Beth Devine. Arch Dermatol 2012
Vincent W Lin, Sarah Ringold, Emily Beth Devine. Arch Dermatol 2012
40
Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
N Woolacott, N Hawkins, A Mason, A Kainth, Z Khadjesari, Y Bravo Vergel, K Misso, K Light, R Chalmers, M Sculpher,[...]. Health Technol Assess 2006
N Woolacott, N Hawkins, A Mason, A Kainth, Z Khadjesari, Y Bravo Vergel, K Misso, K Light, R Chalmers, M Sculpher,[...]. Health Technol Assess 2006
40
Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
Kristian Reich, Rodney Sinclair, Graeme Roberts, Christopher E M Griffiths, Maggie Tabberer, Jonathan Barker. Curr Med Res Opin 2008
Kristian Reich, Rodney Sinclair, Graeme Roberts, Christopher E M Griffiths, Maggie Tabberer, Jonathan Barker. Curr Med Res Opin 2008
40
Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.
April W Armstrong, Keith A Betts, James E Signorovitch, Murali Sundaram, Junlong Li, Arijit X Ganguli, Eric Q Wu. Curr Med Res Opin 2018
April W Armstrong, Keith A Betts, James E Signorovitch, Murali Sundaram, Junlong Li, Arijit X Ganguli, Eric Q Wu. Curr Med Res Opin 2018
40
Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review.
Andrew Blauvelt, Russel Burge, William Malatestinic, Alan Brnabic, Jiaying Guo, Manju Janardhanan, Baojin Zhu. J Manag Care Spec Pharm 2021
Andrew Blauvelt, Russel Burge, William Malatestinic, Alan Brnabic, Jiaying Guo, Manju Janardhanan, Baojin Zhu. J Manag Care Spec Pharm 2021
100
Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
L M Sawyer, L Cornic, L Å Levin, C Gibbons, A H Møller, G B Jemec. J Eur Acad Dermatol Venereol 2019
L M Sawyer, L Cornic, L Å Levin, C Gibbons, A H Møller, G B Jemec. J Eur Acad Dermatol Venereol 2019
40
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.
R B Warren, A Blauvelt, Y Poulin, S Beeck, M Kelly, T Wu, Z Geng, C Paul. Br J Dermatol 2021
R B Warren, A Blauvelt, Y Poulin, S Beeck, M Kelly, T Wu, Z Geng, C Paul. Br J Dermatol 2021
40
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Kristian Reich, April W Armstrong, Peter Foley, Michael Song, Yasmine Wasfi, Bruce Randazzo, Shu Li, Y-K Shen, Kenneth B Gordon. J Am Acad Dermatol 2017
Kristian Reich, April W Armstrong, Peter Foley, Michael Song, Yasmine Wasfi, Bruce Randazzo, Shu Li, Y-K Shen, Kenneth B Gordon. J Am Acad Dermatol 2017
40
Bimekizumab versus Secukinumab in Plaque Psoriasis.
Kristian Reich, Richard B Warren, Mark Lebwohl, Melinda Gooderham, Bruce Strober, Richard G Langley, Carle Paul, Dirk De Cuyper, Veerle Vanvoorden, Cynthia Madden,[...]. N Engl J Med 2021
Kristian Reich, Richard B Warren, Mark Lebwohl, Melinda Gooderham, Bruce Strober, Richard G Langley, Carle Paul, Dirk De Cuyper, Veerle Vanvoorden, Cynthia Madden,[...]. N Engl J Med 2021
40
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY).
J Bagel, A Blauvelt, J Nia, P Hashim, M Patekar, A de Vera, K Ahmad, B Paguet, S Xia, E Muscianisi,[...]. J Eur Acad Dermatol Venereol 2021
J Bagel, A Blauvelt, J Nia, P Hashim, M Patekar, A de Vera, K Ahmad, B Paguet, S Xia, E Muscianisi,[...]. J Eur Acad Dermatol Venereol 2021
40
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, Ruquan You,[...]. J Am Acad Dermatol 2015
Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, Ruquan You,[...]. J Am Acad Dermatol 2015
40
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
40
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Kenneth B Gordon, Peter Foley, James G Krueger, Andreas Pinter, Kristian Reich, Ronald Vender, Veerle Vanvoorden, Cynthia Madden, Katy White, Christopher Cioffi,[...]. Lancet 2021
Kenneth B Gordon, Peter Foley, James G Krueger, Andreas Pinter, Kristian Reich, Ronald Vender, Veerle Vanvoorden, Cynthia Madden, Katy White, Christopher Cioffi,[...]. Lancet 2021
40
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Kristian Reich, Kim A Papp, Andrew Blauvelt, Richard G Langley, April Armstrong, Richard B Warren, Kenneth B Gordon, Joseph F Merola, Yukari Okubo, Cynthia Madden,[...]. Lancet 2021
Kristian Reich, Kim A Papp, Andrew Blauvelt, Richard G Langley, April Armstrong, Richard B Warren, Kenneth B Gordon, Joseph F Merola, Yukari Okubo, Cynthia Madden,[...]. Lancet 2021
40
Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.
Carle Paul, Christopher E M Griffiths, Peter C M van de Kerkhof, Lluís Puig, Yves Dutronc, Carsten Henneges, Martin Dossenbach, Kristin Hollister, Kristian Reich. J Am Acad Dermatol 2019
Carle Paul, Christopher E M Griffiths, Peter C M van de Kerkhof, Lluís Puig, Yves Dutronc, Carsten Henneges, Martin Dossenbach, Kristin Hollister, Kristian Reich. J Am Acad Dermatol 2019
40
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Kristian Reich, April W Armstrong, Richard G Langley, Susan Flavin, Bruce Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt. Lancet 2019
Kristian Reich, April W Armstrong, Richard G Langley, Susan Flavin, Bruce Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt. Lancet 2019
40
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth Gordon, Jolanta Weglowska, Lluis Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco Kerdel,[...]. N Engl J Med 2015
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth Gordon, Jolanta Weglowska, Lluis Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco Kerdel,[...]. N Engl J Med 2015
40
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley,[...]. Lancet 2018
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley,[...]. Lancet 2018
40
Bimekizumab versus Adalimumab in Plaque Psoriasis.
Richard B Warren, Andrew Blauvelt, Jerry Bagel, Kim A Papp, Paul Yamauchi, April Armstrong, Richard G Langley, Veerle Vanvoorden, Dirk De Cuyper, Christopher Cioffi,[...]. N Engl J Med 2021
Richard B Warren, Andrew Blauvelt, Jerry Bagel, Kim A Papp, Paul Yamauchi, April Armstrong, Richard G Langley, Veerle Vanvoorden, Dirk De Cuyper, Christopher Cioffi,[...]. N Engl J Med 2021
40
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, Bruce Randazzo, Yasmine Wasfi, Yaung-Kaung Shen, Shu Li, Alexa B Kimball. J Am Acad Dermatol 2017
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, Bruce Randazzo, Yasmine Wasfi, Yaung-Kaung Shen, Shu Li, Alexa B Kimball. J Am Acad Dermatol 2017
40
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Stephen Tyring, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Ronald Vender, Sophie Hugot,[...]. J Am Acad Dermatol 2017
Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Stephen Tyring, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Ronald Vender, Sophie Hugot,[...]. J Am Acad Dermatol 2017
40
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.
April W Armstrong, Charlotte Read. JAMA 2020
April W Armstrong, Charlotte Read. JAMA 2020
40
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.
Philip J Mease, Iain B McInnes, Lai-Shan Tam, Kiefer Eaton, Steve Peterson, Agata Schubert, Soumya D Chakravarty, Anna Parackal, Chetan S Karyekar, Sandhya Nair,[...]. Rheumatology (Oxford) 2021
Philip J Mease, Iain B McInnes, Lai-Shan Tam, Kiefer Eaton, Steve Peterson, Agata Schubert, Soumya D Chakravarty, Anna Parackal, Chetan S Karyekar, Sandhya Nair,[...]. Rheumatology (Oxford) 2021
20
Comparison of two independent systematic reviews of trials of recombinant human bone morphogenetic protein-2 (rhBMP-2): the Yale Open Data Access Medtronic Project.
Jeffrey Low, Joseph S Ross, Jessica D Ritchie, Cary P Gross, Richard Lehman, Haiqun Lin, Rongwei Fu, Lesley A Stewart, Harlan M Krumholz. Syst Rev 2017
Jeffrey Low, Joseph S Ross, Jessica D Ritchie, Cary P Gross, Richard Lehman, Haiqun Lin, Rongwei Fu, Lesley A Stewart, Harlan M Krumholz. Syst Rev 2017
20
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.